Please assess the completion status of the following clinical trial:

Trial Title: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (IMWG criteria)~* Measurable disease, as defined by at least 1 of the following~  1. Serum myeloma (M) protein ≥0.5 g/dL (5 g/L)~ 2. Urine M protein ≥200 mg/24 h~ 3. Serum free light chain (FLC) \>100 mg/L (10 mg/dL) with abnormal kappa:lambda ratio~* Participants must have progressed on or been intolerant of at least 3 prior therapies including proteasome inhibitor, IMID drug and anti-CD38 antibody, either in combination or as a single agent~* ECOG PS 0, 1 or 2. PS 3 is permitted if PS is due solely to bone pain~* Adequate bone marrow, hematological, kidney and liver function~* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1~* Not pregnant and willing to use contraception~Exclusion Criteria:~* POEMS syndrome~* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ~* History of active autoimmune disorders~* Any form of primary immunodeficiency~* History of severe immune-mediated adverse event with prior immunomodulatory treatment~* Stem cell transplant within 12 weeks prior to enrollment~* Active graft versus host disease other than Grade 1 skin involvement, or that requiring immunosuppressive treatment~* Requirement for systemic immune suppressive medication~* Active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, known HIV or AIDS related illness and SARS-CoV2~* Previous administration with an investigational drug within 4 weeks or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)~* Known or suspected hypersensitivity to component of elranatamab (PF-06863135), murine and bovine products~* Live attenuated vaccine within 4 weeks

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elranatamab (PF-06863135) (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).